Lynparza phase III PROfound trial in HRR mutationselected metastatic castrationresistant prostate cancer met primary endpoint

Lynparza phase III PROfound trial in HRR mutation-selected metastatic castration-resistant prostate cancer met primary endpoint

Results from the trial showed a statistically-significant and clinically-meaningful improvement in the primary endpoint of radiographic progression-free survival (rPFS) with Lynparza vs. enzalutamide or abiraterone in men with

More From BioPortfolio on "Lynparza phase III PROfound trial in HRR mutation-selected metastatic castration-resistant prostate cancer met primary endpoint"